Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Pfizer Loses Its Triple-A Credit Rating

Posted by: Ben Steverman on October 16, 2009

The Triple-A credit rating is disappearing before our eyes. On Oct. 16, Standard & Poor’s yanked drug maker Pfizer’s (PFE) AAA-rating, the best rating the agency can give out to credit-worthy companies.

The move was no surprise. Pfizer sealed its fate when it launched its $66.9 billion acquisition of rival pharmaceutical firm Wyeth, a deal that was completed on Oct. 15. Buying Wyeth required borrowing $22.5 billion.

S&P credit analyst David Lugg said in a statement that Pfizer’s new, lower “AA” rating reflects:

… the challenge to realize earnings and cash flow benefits in light of pending patent expirations in the midst of a currently difficult market as well as the significant additional borrowings needed to fund the [Wyeth] acquisition.

As S&P’s managing direction Nicholas Riccio told me in March, the AAA credit rating is “almost extinct at this point in Corporate America.”

General Electric (GE) lost its triple-A rating in March. Only four firms still have S&P’s top credit rating: ExxonMobil (XOM), Johnson & Johnson (JNJ), Automatic Data Processing (ADP) and Microsoft (MSFT). In late 1994, 14 compaines had triple-A ratings.

It’s easy to blame the disappearance of the top rating on economic hard times. But it also reflects shifting priorities for CEOs, corporate boards and investors. Pfizer execs knew the Wyeth deal would hurt its sterling credit reputation, but they completed the deal anyway — obviously for strategic reasons they see as more important than the recommendation of the credit rating agencies.

(S&P, like BusinessWeek, is a unit of the McGraw-Hill Companies.)

Reader Comments


October 18, 2009 8:50 PM

Pfizer Forcing U.S. Citizens
to Train H-1B
Pfizer Forcing U.S. Citizens to Train
H-1B Guest Worker Replacements Before Being Fired. This is one of the most disgusting and egregious corporate acts I can think of. Unfortunately we have heard this story repeatedly. Professionals have testified before Congress and multiple reports have witnessed this despicable treatment before throwing away U.S. workers. Even worse, corporations intimidate and send fear into workers by withholding their severance, imply the worker will receive a bad job reference or the cruelest joke of maybe, just maybe they will be able to keep their job (which of course is a lie). The Day documents the psychological torture: NO ONE would need Free Drugs if Americans were not being replaced with H-1B's.

Post a comment



Bloomberg Businessweek’s Ben Steverman focuses on the latest moves in financial markets and emerging trends in stocks, bonds, and funds, always with an eye toward giving readers a better understanding of the sometimes confusing and often chaotic world of money. Standard & Poor’s senior index analyst Howard Silverblatt will also provide his take on companies’ finances and the markets. Voted one of the “Top 100 Finance Blogs” in 2007.

BW Mall - Sponsored Links

Buy a link now!